The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases

Taylor A, Kosoff D, Emamekhoo H, Lang J, Kyriakopoulos C . PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023; 13:1159557. PMC: 10165068. DOI: 10.3389/fonc.2023.1159557. View

OBrien M, Schwartz A, Plattner L . Treat the Pain Program. J Pain Symptom Manage. 2017; 55(2S):S135-S139. DOI: 10.1016/j.jpainsymman.2017.03.033. View

Ashley T, Ashley H, Wladis A, Bolkan H, van Duinen A, Beard J . Outcomes After Elective Inguinal Hernia Repair Performed by Associate Clinicians vs Medical Doctors in Sierra Leone: A Randomized Clinical Trial. JAMA Netw Open. 2021; 4(1):e2032681. PMC: 7801936. DOI: 10.1001/jamanetworkopen.2020.32681. View

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

Woods B, Sideris E, Sydes M, Gannon M, Parmar M, Alzouebi M . Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. Eur Urol Oncol. 2019; 1(6):449-458. PMC: 6692495. DOI: 10.1016/j.euo.2018.06.004. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Extermann M, Brain E, Canin B, Cherian M, Cheung K, de Glas N . Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Lancet Oncol. 2021; 22(1):e29-e36. DOI: 10.1016/S1470-2045(20)30473-3. View

Loeb S, Sengupta S, Butaney M, Macaluso Jr J, Czarniecki S, Robbins R . Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube. Eur Urol. 2018; 75(4):564-567. DOI: 10.1016/j.eururo.2018.10.056. View

Wang C, Hu C, Gao D, Zhao Z, Chen X, Hu X . Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2018; 83(3):509-517. DOI: 10.1007/s00280-018-3754-x. View

10.

Kretschmer A, Tilki D . Biomarkers in prostate cancer - Current clinical utility and future perspectives. Crit Rev Oncol Hematol. 2017; 120:180-193. DOI: 10.1016/j.critrevonc.2017.11.007. View

11.

Francini E, Gray K, Xie W, Shaw G, Valenca L, Bernard B . Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018; 78(12):889-895. PMC: 6171350. DOI: 10.1002/pros.23645. View

12.

Clarke C, Hunter R, Gabrio A, Brawley C, Ingleby F, Dearnaley D . Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS One. 2022; 17(6):e0269192. PMC: 9162346. DOI: 10.1371/journal.pone.0269192. View

13.

Halabi S, Dutta S, Tangen C, Rosenthal M, Petrylak D, Thompson Jr I . Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2018; 37(5):403-410. PMC: 6804881. DOI: 10.1200/JCO.18.01279. View

14.

Sokhi H, Padhani A, Patel S, Pope A . Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. Clin Radiol. 2020; 75(12):950-956. DOI: 10.1016/j.crad.2020.08.011. View

15.

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan K, Santhappan S . Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol. 2020; 6:1063-1075. PMC: 7392737. DOI: 10.1200/GO.20.00122. View

16.

Niaz M, Sun M, Skafida M, Niaz M, Ivanidze J, Osborne J . Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. Clin Imaging. 2021; 79:278-288. DOI: 10.1016/j.clinimag.2021.06.006. View

17.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

18.

Freund K, Battaglia T, Calhoun E, Darnell J, Dudley D, Fiscella K . Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014; 106(6):dju115. PMC: 4072900. DOI: 10.1093/jnci/dju115. View

19.

Loeb S, Taylor J, Butaney M, Byrne N, Gao L, Soule H . Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination. Eur Urol. 2019; 75(5):881-882. DOI: 10.1016/j.eururo.2019.01.025. View

20.

Hanna S, Gouveia A, Moraes F, Rosa A, Arruda Viani G, Massuda A . Lessons from the Brazilian radiotherapy expansion plan: A project database study. Lancet Reg Health Am. 2023; 14:100333. PMC: 9903577. DOI: 10.1016/j.lana.2022.100333. View